{
  "items": [
    {
      "id": "iLRx3LV_",
      "url": "https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-second-half-2025",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Jul 2, 2025 10:19am",
      "snippet": "In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "E9KnfVkc",
      "url": "https://www.fiercepharma.com/pharma/amgens-chemocentryx-prevails-investor-lawsuit-around-autoimmune-drug-tavneos",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 19, 2025 9:58am",
      "snippet": "Dogged for several years by an investor lawsuit accusing the company of misleading investors about the safety and efficacy of its now-approved drug Tavneos, ChemoCentryx has emerged victorious in a securities fraud complaint.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "NuL2YO87",
      "url": "https://www.fiercepharma.com/biotech/csl-lay-15-workforce-cut-rd-costs-and-spin-out-vaccine-unit",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 19, 2025 4:33am",
      "snippet": "CSL is laying off up to 15% of its workforce as the company looks to cut R&amp;D costs and spin out its vaccine subsidiary.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "cmAQkVRF",
      "url": "https://www.fiercepharma.com/pharma/sarepta-shares-more-elevidys-safety-data-response-patient-group-fda-petition",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 18, 2025 10:56am",
      "snippet": "Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy patient group petitions the FDA to update the medicine’s label.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "39MdEmWV",
      "url": "https://www.fiercepharma.com/pharma/vanda-scores-landmark-win-over-fda-years-long-dispute-over-hetlioz-jet-lag-disorder-bid",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 18, 2025 11:05am",
      "snippet": "An appeals court overturned a prior FDA action in a years-long face-off between Vanda and the agency over a delayed hearing for Vanda's jet lag disorder hopeful Hetlioz.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "obQiuMuC",
      "url": "https://www.fiercepharma.com/marketing/novo-nordisk-unveils-499-cash-pay-ozempic-offering-amid-continued-compounder-competition",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 18, 2025 11:02am",
      "snippet": "Several months after unveiling its direct-to-consumer NovoCare Pharmacy service with the launch of a $499 cash-pay option for a monthly supply of Wegovy, Novo Nordisk is expanding the discount to its other GLP-1 heavyweight.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6000000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 1,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "wEapQErW",
      "url": "https://www.fiercepharma.com/pharma/conflicts-interests-cdcs-vaccine-panel-historic-low-when-rfk-jrs-hhs-purged-committee-remove",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 15, 2025 2:02pm",
      "snippet": "Earlier this summer, HHS Secretary Robert F. Kennedy ousted all members of the CDC's vaccine advisory committee in an effort to remove industry influence. But according to a new study, industry-related conflicts of influence had already been \"virtually eliminated\" for years.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "ggwcuujR",
      "url": "https://www.fiercepharma.com/pharma/novos-wegovy-picks-3rd-indication-fda-approval-severe-liver-disease-mash",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 18, 2025 9:43am",
      "snippet": "The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis. The green light tees up a likely showdown with Madrigal Pharmaceuticals' approved drug Rezdiffra in the severe form of fatty liver diseas",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "r8f2E2W9",
      "url": "https://www.fiercepharma.com/sponsored/ai-media-and-evolution-omnichannel-healthcare-marketing-ray-rosti-episode-3-next",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 6, 2025 3:50pm",
      "snippet": "Klick Media’s President shares his perspective on how AI is redefining planning, analytics and micro-segmentation in HCP marketing",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "sq_FYhOq",
      "url": "https://www.fiercepharma.com/sponsored/fedegaris-fob5-redefines-sterilization-compact-design-and-full-gmp-compliance",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 13, 2025 9:58am",
      "snippet": "Discover how Fedegari’s FOB5 is redefining sterilization with compact design, GMP compliance &amp; high-containment capabilities.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6500000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 2,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "MSWET-B-",
      "url": "https://www.fiercepharma.com/pharma/fiercest-women-life-sciences-2025-nominations-open-now",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 15, 2025 12:13pm",
      "snippet": "Every year, Fierce celebrates women making a powerful impact across biopharma and medtech. It’s time once again to make your suggestions for this year’s honorees.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Q47GYJPj",
      "url": "https://www.fiercepharma.com/pharma/tonixs-tonmya-gains-fda-nod-becoming-first-new-fibromyalgia-treatment-more-16-years",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 15, 2025 4:57pm",
      "snippet": "Tonix Pharmaceuticals was founded in 2010 to develop and bring to market a drug for fibromyalgia. Fifteen years later, the New Jersey company has accomplished its mission with an FDA sign-off for Tonmya.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "hf_-AEV3",
      "url": "https://www.fiercepharma.com/pharma/lundbeck-dials-migraine-drug-us-peak-sales-stays-positive-rexulti-ptsd-use",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 15, 2025 10:09am",
      "snippet": "After a 54% year-over-year sales increase for CGRP migraine drug Vyepti in the U.S., Lundbeck has raised its peak sales projection for the therapy in the key market.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Q5dhOn4c",
      "url": "https://www.fiercepharma.com/pharma/amgen-skirts-50m-payout-blincyto-patent-litigation-tiff-lindis",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 15, 2025 9:55am",
      "snippet": "U.S. District Judge Gregory Williams concluded that two patents held by Lindis Biotech “are unenforceable due to inequitable conduct.” The decision negates the $50.3 million jury verdict Lindis won in December over allegations that Amgen’s Blincyto violated Lindis-held intellectu",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "5NU13kkc",
      "url": "https://www.fiercepharma.com/marketing/astrazeneca-begins-dtc-home-delivery-self-administered-flumist-vaccine",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 15, 2025 10:06am",
      "snippet": "Nearly a year after earning the first-ever FDA approval for a self-administered flu vaccine, AstraZeneca has kicked off a new service delivering its FluMist directly to consumers.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "3bf7N8mT",
      "url": "https://www.fiercepharma.com/pharma/battle-obesity-drug-heavyweights",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 14, 2025 3:22pm",
      "snippet": "In this episode of \"The Top Line,\" we unpack how Novo Nordisk and Eli Lilly’s latest earnings, pipeline moves and rising competition are reshaping the high-stakes race in obesity drugs.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "wLSsQrK1",
      "url": "https://www.fiercepharma.com/pharma/precigen-scores-fda-nod-first-ever-treatment-hpv-related-disorder",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 15, 2025 8:21am",
      "snippet": "The FDA has approved a treatment for recurrent respiratory papillomatosis for the first time. The agency has signed off on Precigen’s Papzimeos, a non-replicating adenoviral vector-based immunotherapy, which can eliminate the need for repeated surgical interventions to remove ben",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "dUPAgd5K",
      "url": "https://www.fiercepharma.com/pharma/padcev-new-breakthrough-alzheimers-drug-grim-fate-fosun-645m-deal",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 14, 2025 6:00pm",
      "snippet": "The combination of Padcev and Keytruda delivered a phase 3 win in muscle-invasive bladder cancer. China did not renew the conditional approval for a controversial Alzheimer's disease drug. Fosun Pharma is out-licensing its DPP1 inhibitor for up to $645 million. And more.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "OwVw8ghh",
      "url": "https://www.fiercepharma.com/pharma/hhs-revives-90s-task-force-designed-improve-safety-childhood-vaccines",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 14, 2025 3:29pm",
      "snippet": "The Department of Health and Human Services is relaunching a task force focused on the safety of childhood vaccines. The federal panel will be chaired by National Institutes of Health Director Jay Bhattacharya, M.D., Ph.D.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "GXM1SFZj",
      "url": "https://www.fiercepharma.com/pharma/eli-lilly-endorses-trumps-goal-aligning-international-drug-prices",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 14, 2025 1:22pm",
      "snippet": "Eli Lilly said it has \"intensified efforts to&nbsp;align prices across developed countries\" in recent months. Besides a new U.K. price hike, Lilly said it may make other \"necessary pricing adjustments\" by Sept. 1.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "HzWX-jRW",
      "url": "https://www.fiercepharma.com/marketing/enhertu-keytruda-promos-put-az-merck-front-oncology-hcp-marketing-pack-report",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 14, 2025 11:53am",
      "snippet": "An analysis of how cancer drugmakers interact with oncologists found, perhaps unsurprisingly, that those interactions are dominated by therapies boasting a broad reach and targeting the most common cancers.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "yZdh_svo",
      "url": "https://www.fiercebiotech.com/medtech/medtronic-expands-board-chase-ma-efficiencies-activist-investor-takes-stake",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 19, 2025 10:27am",
      "snippet": "The company’s newest stakeholder, Elliott Investment Management, said it has become one of Medtronic's largest investors.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "yKjMYHsv",
      "url": "https://www.fiercebiotech.com/biotech/ptc-therapeutics-friedreichs-ataxia-hopes-derailed-crl-fda",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 19, 2025 10:32am",
      "snippet": "Despite missing its primary endpoint in a phase 3 study, PTC had held out hope that another endpoint would help its candidate pass muster with the FDA.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "QLaQ7spq",
      "url": "https://www.fiercebiotech.com/biotech/fda-pushes-back-pdufa-date-regenxbios-hunter-syndrome-gene-therapy",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 19, 2025 9:08am",
      "snippet": "Delays from the Food and Drug Administration continue to pile up, with Maryland-based Regenxbio the latest to report the review of one of its assets has been extended.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "WFWD2bcx",
      "url": "https://www.fiercebiotech.com/biotech/viking-hits-stormy-seas-phase-2-oral-obesity-data-sink-stock",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 19, 2025 9:21am",
      "snippet": "Viking Therapeutics has reported phase 2 data on its oral obesity drug candidate, linking the peptide to weight loss of up to 12.2% after 13 weeks. But with 38% of patients discontinuing treatment at the most effective dose, investors sent the stock down 37% in premarket trading.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "HXn-b_5P",
      "url": "https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Dec 23, 2024 11:52am",
      "snippet": "As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "I7ZDh7pR",
      "url": "https://www.fiercebiotech.com/biotech/opthea-still-reeling-eye-disease-flops-ramps-layoffs-85-and-loses-ceo",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 19, 2025 5:32am",
      "snippet": "Opthea’s options may be shrinking as the eye disease biotech comes to terms with a pair of phase 3 failures, but the company isn’t quite ready to give up.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.39999999999999997,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 1,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "HwpUXT7x",
      "url": "https://www.fiercebiotech.com/biotech/chinas-remegen-sells-asia-rights-vegffgf-eye-drug-180m-deal",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 19, 2025 6:17am",
      "snippet": "China’s RemeGen has sold certain Asia rights to its phase 3-stage eye disease drug to Japan’s Santen Pharmaceutical for 250 million Chinese yuan ($34.8 million) upfront.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "kiGyxqgi",
      "url": "https://www.fiercebiotech.com/biotech/csl-lay-15-workforce-cut-rd-costs-and-spin-out-vaccine-unit",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 19, 2025 4:33am",
      "snippet": "CSL is laying off up to 15% of its workforce as the company looks to cut R&amp;D costs and spin out its vaccine subsidiary.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "zptqQjZQ",
      "url": "https://www.fiercebiotech.com/biotech/shankar-ramaswamys-gene-therapy-biotech-raises-313m",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 4:29pm",
      "snippet": "Gene therapy biotech Kriya Therapeutics has secured $313 million in a new series fundraise.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "3hjWQvN7",
      "url": "https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Dec 23, 2024 12:22pm",
      "snippet": "The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "5sM6xtXU",
      "url": "https://www.fiercebiotech.com/biotech/genentechs-summer-struggle-continues-scrapped-2b-cell-therapy-deal",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 2:14pm",
      "snippet": "Genentech’s summer of downsizing and cost-cutting continued this morning, with the Roche subsidiary announcing the termination of a cell therapy deal worth as much as $2 billion. The pact with Adaptive Biotechnologies, originally launched in January 2019, was meant to see Genente",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "SbKGbpgW",
      "url": "https://www.fiercebiotech.com/cro/private-equity-firm-acquires-clinical-trial-site-network-headlands-research",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 12:05pm",
      "snippet": "After years of striking acquisitions to build up its site network, Headlands Research has now been bought itself. Headlands has been scooped up by private equity firm THL Partners, which entered an agreement to buy the clinical trial company from founding firm KKR.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "CTGGV_09",
      "url": "https://www.fiercebiotech.com/biotech/stealth-bio-submits-fda-application-rare-disease-candidate-third-time-0",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 11:17am",
      "snippet": "After an FDA rejection in May, Stealth BioTherapeutics has resubmitted a new drug application for its investigational treatment designed to treat an ultra-rare genetic disease.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "0pbvvwzF",
      "url": "https://www.fiercebiotech.com/biotech/neurizon-becomes-second-biotech-hit-fda-delay-als-candidate",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 10:48am",
      "snippet": "Yet another biotech is facing a delay from the Food and Drug Administration as the agency reels from intense staffing cuts. Neurizon, an Australian biotech focusing on neurodegenerative diseases, will now have to wait until Oct. 3 before receiving a response on whether its amyotr",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "pSDNg4Gh",
      "url": "https://www.fiercebiotech.com/medtech/baxters-novum-iq-corrections-grow-scope-include-syringe-pumps",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 11:05am",
      "snippet": "Last month, Baxter and the FDA highlighted a problem with the Novum IQ large-volume pump, tied to 79 serious injuries and two deaths. Now, separate software issues are affecting both the large-volume system as well as its syringe-based pump.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "YPpsaygg",
      "url": "https://www.fiercebiotech.com/biotech/merck-kgaa-swoops-2b-neurological-disease-pact-skyhawk",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 9:35am",
      "snippet": "Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 billion.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "03qKxhSU",
      "url": "https://www.fiercebiotech.com/biotech/reunions-psychedelic-prodrug-reduces-post-partum-depression-phase-2-study",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 5:59am",
      "snippet": "Reunion Neuroscience’s psychedelic has reduced the symptoms of postpregnancy depression in a phase 2 study, setting up the biotech to enter late-stage trials next year.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "w7aObQFo",
      "url": "https://www.fiercebiotech.com/biotech/pfizers-scd-drug-fails-phase-3-study-latest-blow-global-blood-therapeutics-legacy",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 4:48am",
      "snippet": "Pfizer’s sickle cell disease drug has flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "CEkuBT1k",
      "url": "https://www.fiercebiotech.com/pharma/fiercest-women-life-sciences-2025-nominations-open-now",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 15, 2025 12:13pm",
      "snippet": "Every year, Fierce celebrates women making a powerful impact across biopharma and medtech. It’s time once again to make your suggestions for this year’s honorees.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "oyTp2lSp",
      "url": "https://www.fiercepharma.com/pharma/saxenda-knockoff-teva-launches-first-generic-glp-1-obesity",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 28, 2025 2:53pm",
      "snippet": "Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk’s injected Saxenda (liraglutide).",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6000000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 1,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "pqYzpBsa",
      "url": "https://www.fiercepharma.com/pharma/outlook-therapeutics-outlook-dims-fda-snubs-reformulated-avastin-eye-disease-again",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 28, 2025 10:31am",
      "snippet": "For the second time, the FDA has declined to approve Outlook's anti-VEGF drug for the treatment of wet age-related macular degeneration.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "lCHpJPkB",
      "url": "https://www.fiercepharma.com/marketing/maze-therapeutics-referred-federal-marketing-regulators-over-challenge-brought-vertex",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 28, 2025 10:50am",
      "snippet": "After Maze Therapeutics opted not to participate in the National Advertising Division’s self-regulatory process for monitoring promotional claims, a case brought by competitor Vertex Pharmaceuticals is being escalated to federal authorities.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "JDYzTXmg",
      "url": "https://www.fiercepharma.com/pharma/roche-begins-construction-7000m-obesity-drug-manufacturing-facility-north-carolina",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 28, 2025 7:32am",
      "snippet": "Roche’s U.S. subsidiary Genentech broke ground Monday on a $700 million plant tabbed for operation in 2029. The fill-finish plant, which will help produce obesity drugs, is part of Roche’s plan to invest $50 billion in the U.S. over the next five years.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "g2ituYev",
      "url": "https://www.fiercepharma.com/pharma/pfizer-biontech-pick-fda-approval-years-updated-mrna-covid-shot",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 27, 2025 1:15pm",
      "snippet": "Amid uncertainty over how the Trump administration would approach mRNA vaccines for the upcoming COVID-19 season, the FDA has approved updated shots from Pfizer and Moderna. But rather than granting the broad endorsements the vaccines previously enjoyed, the administration is res",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "osC32Q-Q",
      "url": "https://www.fiercepharma.com/biotech/exelixis-lay-130-employees-shut-down-pennsylvania-site-post-pandemic-downsizing",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 27, 2025 2:03pm",
      "snippet": "Mere months after its cancer blockbuster hopeful topped Bayer’s Stivarga in a phase 3 trial, Exelixis is conducting a reorganization that will see the oncology company’s Pennsylvania site wind down and 130 employees laid off, a company spokesperson confirmed to Fierce Biotech.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "JNIwGL1l",
      "url": "https://www.fiercepharma.com/pharma/remegen-vor-bio-score-again-telitacicept-time-igan",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 27, 2025 10:28am",
      "snippet": "China biotech RemeGen and its new U.S. partner Vor Bio are on a roll with their first-in-class autoimmune treatment telitacicept. Two weeks after revealing the success of a phase 3 trial of telitacicept in&nbsp;Sjögren’s disease, the companies have reported another late-stage win",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "XofKqA8j",
      "url": "https://www.fiercepharma.com/marketing/clevelanddx-reboots-psa-psa-campaign-drive-prostate-cancer-screening",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 26, 2025 5:25pm",
      "snippet": "For the third year in a row, Cleveland Diagnostics is commemorating September’s Prostate Cancer Awareness Month with its “A PSA on PSA” campaign that serves as a public service announcement about prostate-specific antigen testing.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "1CA42Vv2",
      "url": "https://www.fiercepharma.com/pharma/excelltheras-novel-blood-cancer-stem-cell-therapy-zemcelpro-earns-eu-nod",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 21, 2025 11:59am",
      "snippet": "The therapy offers a more accessible option to patients with hematological malignancies (blood cancers) who don't have access to suitable donor cells for traditional stem cell transplants.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "48X_szKG",
      "url": "https://www.fiercepharma.com/health-tech/eversana-waltz-health-merge-and-form-combined-pharmaceutical-pricing-platform",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 26, 2025 1:35pm",
      "snippet": "The deal will bring together Waltz's proprietary drug marketplaces and direct-to-payer model with Eversana's global pharmaceutical commercialization platform.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "l85IuwPi",
      "url": "https://www.fiercepharma.com/biotech/8-months-after-bergers-departure-sanofi-snags-biomarin-leader-take-cmo-role",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 26, 2025 11:10am",
      "snippet": "Eight months after Sanofi’s former Chief Medical Officer, Dietmar Berger, M.D., departed, the French drugmaker has selected a successor.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "esGxOHrr",
      "url": "https://www.fiercebiotech.com/biotech/fda-considers-non-invasive-liver-endpoint-trials-sending-mash-biotechs-stock",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 28, 2025 10:45am",
      "snippet": "The FDA has begun considering a noninvasive liver measurement as a surrogate endpoint for certain MASH patients, a move that could speed up drug development in the space.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "tlp3gYEs",
      "url": "https://www.fiercebiotech.com/medtech/fda-flags-issues-review-telixs-pet-diagnostic-agent-kidney-cancer",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 28, 2025 10:57am",
      "snippet": "The FDA has asked Telix for more information about the manufacturing of its novel PET agent for clear-cell renal cell carcinoma.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "W5ACIv4n",
      "url": "https://www.fiercebiotech.com/biotech/flagship-pioneering-taps-iqvia-biotech-support-company-fleet",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 28, 2025 10:54am",
      "snippet": "Flagship Pioneering is boosting the clinical research capabilities of its biotech fleet with a new IQVIA collaboration. The CRO giant will provide Flagship’s companies with its artificial intelligence and clinical trial technologies to enhance their drug development and early com",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6000000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 1,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "MeqS5Oor",
      "url": "https://www.fiercebiotech.com/biotech/novo-nordisk-seeks-obesity-refresh-550m-replicate-research-deal",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 27, 2025 5:20pm",
      "snippet": "As obesity pioneer Novo Nordisk loses ground in the race for next-generation drugs, the Danish pharma giant is betting on novel RNA technology to bolster its early-stage pipeline. Novo has inked a multiyear research collaboration with Replicate Bioscience potentially worth $550 m",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "TXA6rW8g",
      "url": "https://www.fiercebiotech.com/biotech/prothenas-alzheimers-trial-hit-aria-showstopper-resulting-non-competitive-profile",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 28, 2025 6:17am",
      "snippet": "A phase 1 study has linked Prothena’s anti-amyloid beta antibody to a higher rate of brain swelling than rival approved drugs, hindering the biotech’s positioning in early symptomatic Alzheimer’s disease.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "G3h21_0z",
      "url": "https://www.fiercebiotech.com/biotech/exelixis-lay-130-employees-shut-down-pennsylvania-site-post-pandemic-downsizing",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 27, 2025 2:03pm",
      "snippet": "Mere months after its cancer blockbuster hopeful topped Bayer’s Stivarga in a phase 3 trial, Exelixis is conducting a reorganization that will see the oncology company’s Pennsylvania site wind down and 130 employees laid off, a company spokesperson confirmed to Fierce Biotech.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "fNCrS30D",
      "url": "https://www.fiercebiotech.com/research/new-foundation-microsoft-co-founder-unveils-inaugural-research-grants-plans-500m-giving",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 27, 2025 11:36am",
      "snippet": "A new foundation from the estate of late Microsoft co-founder Paul Allen has launched with a set of four research grant recipients and plans to give $500 million over the next four years to support progress in bioscience, environmental science and AI development.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "B6LYrCkU",
      "url": "https://www.fiercebiotech.com/biotech/nykode-sticks-its-neck-out-betting-future-phase-2-cancer-trial-after-losing-genentech-pact",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 27, 2025 7:38am",
      "snippet": "Nykode Therapeutics has designed a two-year plan to turn its fortunes around. Having lost a deal with Genentech—and with the future of a Regeneron pact uncertain—the Norwegian biotech is focusing on delivering phase 2 data in head and neck cancer before its cash runway runs out.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "kXkuKpEW",
      "url": "https://www.fiercebiotech.com/biotech/wugen-woos-vcs-landing-115m-bring-fratricide-proof-car-t-cell-therapy-market",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 27, 2025 8:53am",
      "snippet": "Wugen has raised $115 million, tapping a Fidelity-led syndicate to fund its pursuit of FDA approval for the first off-the-shelf CAR-T for T-cell malignancies. A pivotal trial is underway, putting the company on track to seek approval in 2027.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "C2nXfUAU",
      "url": "https://www.fiercebiotech.com/cro/chinese-cro-chempartner-announces-new-boston-research-facility",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 26, 2025 2:29pm",
      "snippet": "Chinese contract research and manufacturing outfit ChemPartner is building out its U.S. footprint in the heart of the bustling Boston biotech scene. The company’s new Boston Center of Excellence is set to open in Watertown, Massachusetts, on Sept. 10, ChemPartner announced in an ",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "1YIn8XvZ",
      "url": "https://www.fiercebiotech.com/biotech/forbion-orbimed-backed-sitala-seals-670m-deal-fosun-immune-disease-drug",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 26, 2025 2:25pm",
      "snippet": "Right on the heels of a similar deal, Fosun Pharma has outlicensed a second inflammatory disease candidate to a Western biotech startup.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "qmBHbpSz",
      "url": "https://www.fiercebiotech.com/biotech/8-months-after-bergers-departure-sanofi-snags-biomarin-leader-take-cmo-role",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 26, 2025 11:10am",
      "snippet": "Eight months after Sanofi’s former Chief Medical Officer, Dietmar Berger, M.D., departed, the French drugmaker has selected a successor.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "zwsF8YJH",
      "url": "https://www.fiercebiotech.com/research/lineage-cell-therapeutics-tunes-hearing-loss-transplant-12m-research-pact",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 26, 2025 10:47am",
      "snippet": "Lineage Cell Therapeutics has found an experienced hearing loss partner to advance a potentially novel transplant for auditory neurons. William Demant Invest, the largest shareholder of Danish hearing aid manufacturer Demant, has earmarked up to $12 million to support preclinical",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "jEAQFrIQ",
      "url": "https://www.fiercebiotech.com/biotech/regeneron-reports-phase-3-win-advancing-push-muscle-myasthenia-gravis",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 26, 2025 9:03am",
      "snippet": "Regeneron has reported a phase 3 win in generalized myasthenia gravis, positioning the biotech to file for FDA approval of its siRNA candidate in the increasingly competitive neuromuscular disease.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "oz0P6P2y",
      "url": "https://www.fiercebiotech.com/biotech/novartis-pens-30m-upfront-bioarctic-pact-pair-seek-out-neurodegeneration-meds",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 26, 2025 2:52am",
      "snippet": "Novartis is putting down $30 million, with a potential $772 million on the line, to work with BioArctic’s tech to find a new drug in the neurodegeneration space.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "RgNFjlYK",
      "url": "https://www.fiercepharma.com/pharma/pd-1xvegf-first-os-win-fosun-sitala-670m-deal-hutchmed-acting-ceo",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 28, 2025 3:36pm",
      "snippet": "Akeso and Summit Therapeutics' PD-1xVEGF drug has delivered its first overall survival win in a phase 3 trial. Fosun Pharma out-licensed another immune disease candidate. Hutchmed's CEO took medical leave. And more.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "WAC_HO5x",
      "url": "https://www.fiercepharma.com/marketing/lilly-links-jd-health-dtc-obesity-diabetes-drug-sales-china",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 29, 2025 10:02am",
      "snippet": "Amid a growing push for more direct-to-consumer access to some of the world’s most popular drugs, Eli Lilly has inked a deal with China’s JD Health to sell its obesity, Type 2 diabetes and alopecia areata meds in the country through a digital health platform.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "ozu9grr-",
      "url": "https://www.fiercepharma.com/pharma/university-michigan-sues-astrazeneca-targeting-influenza-master-strains-used-flumist",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 29, 2025 9:40am",
      "snippet": "The University of Michigan is suing AstraZeneca over claims that the British drugmaker continues to market and sell FluMist despite not renewing a key contract with the school that was crucial to the vaccine's development.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "R2Cu3zua",
      "url": "https://www.fiercebiotech.com/biotech/fosun-rises-again-inking-3rd-inflammatory-disease-deal-3-weeks",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 29, 2025 9:33am",
      "snippet": "Fosun Pharma has penned its third inflammatory disease pact in three weeks, plucking up China rights to a clinical-stage treatment from Accro Bioscience.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "AW3x9TmF",
      "url": "https://www.fiercebiotech.com/biotech/beone-hits-primary-endpoint-setting-stage-filings-take-blood-cancer-mantle",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 29, 2025 9:25am",
      "snippet": "A phase 1/2 trial of BeOne Medicines’ sonrotoclax has hit its primary endpoint, furthering the biotech’s plans to launch the first BCL2 inhibitor for use in mantle cell lymphoma.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "bAHaZ3S6",
      "url": "https://www.fiercebiotech.com/biotech/chutes-ladders-sanofi-snags-cmo-biomarin",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 28, 2025 4:58pm",
      "snippet": "Eight months after Sanofi’s former chief medical officer, Dietmar Berger, M.D., departed, the French drugmaker has selected Marcia Kayath, M.D., Ph.D., to fill the role. Kayath will start in her new role at Sanofi Sept. 2 and will report to Sanofi’s R&amp;D head, Houman Ashrafian",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "FJlm9QIp",
      "url": "https://www.fiercepharma.com/pharma/sanofi-rilzabrutinib-fda-approval-immune-thrombocytopenia-itp",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 14, 2025 3:32pm",
      "snippet": "While Sanofi originally had its eye on tolebrutinib when it purchased its partner Principia Biopharma for $3.7 billion, another of the biotech’s BTK inhibitors has made it across the FDA finish line first.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "Jl-gNoaw",
      "url": "https://www.fiercepharma.com/pharma/eisai-secures-highly-anticipated-fda-green-light-leqembi-iqlik-autoinjector-teeing-home",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 29, 2025 12:15pm",
      "snippet": "The FDA has&nbsp;approved a once-weekly subcutaneous maintenance dose of Leqembi in an autoinjector, dubbed Leqembi IQLIK, which Eisai has hailed as a key milestone in its quest to grow the reach of the Alzheimer's disease medicine. With a green light in hand, Eisai will also pro",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "ko-HReXU",
      "url": "https://www.fiercepharma.com/biotech/zydus-phase-3-liver-disease-win-tees-filing-challenge-gilead-and-ipsen",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 29, 2025 10:50am",
      "snippet": "Zydus Therapeutics has racked up a phase 2b/3 win in primary biliary cholangitis, clearing the path to a filing to establish the company as a challenger to Gilead, Intercept Pharmaceuticals and Ipsen.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "-4tYW29z",
      "url": "https://www.fiercepharma.com/pharma/after-trial-failure-jj-halts-imaavy-combo-agent-rheumatoid-arthritis",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 29, 2025 10:19am",
      "snippet": "Flying high after an FDA approval four months ago to treat generalized myasthenia gravis, Johnson &amp; Johnson’s much-touted Imaavy has taken a hit, coming up short as part of a combination therapy in a rheumatoid arthritis trial.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "aNNtHuiB",
      "url": "https://www.fiercepharma.com/pharma/pfizer-discontinue-low-dose-attr-drug-vyndaqel-us-ahead-2028-patent-loss",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 29, 2025 10:02am",
      "snippet": "Pfizer is taking a curtain call for Vyndaqel, the low-dose version of its blockbuster tafamidis franchise for the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM).",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "I2FNlw_a",
      "url": "https://www.fiercebiotech.com/biotech/zydus-phase-3-liver-disease-win-tees-filing-challenge-gilead-and-ipsen",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 29, 2025 10:50am",
      "snippet": "Zydus Therapeutics has racked up a phase 2b/3 win in primary biliary cholangitis, clearing the path to a filing to establish the company as a challenger to Gilead, Intercept Pharmaceuticals and Ipsen.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "6Rdtmhxp",
      "url": "https://www.fiercepharma.com/pharma/intercept-pulls-liver-disease-drug-ocaliva-us-after-regulatory-struggles-fda-orders-clinical",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 11, 2025 10:33am",
      "snippet": "The FDA has officially put its foot down on Intercept Pharmaceuticals’ rare liver disease drug Ocaliva, requesting that the company pull the med from the market and putting all of its related trials on a clinical hold.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "PS74tBuG",
      "url": "https://www.fiercepharma.com/pharma/despite-being-designed-seniors-mercks-pneumococcal-shot-excels-trial-children",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 11, 2025 10:33am",
      "snippet": "Approved 15 months ago as a pneumococcal disease vaccine for adults—and billed largely as the first shot designed for seniors—Merck’s Capvaxive has data supporting its potential in children and adolescents from a phase 3 trial.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "YWuDGOBw",
      "url": "https://www.fiercepharma.com/biotech/fibrogen-pays-sec-12m-over-allegations-former-exec-reverse-engineered-roxadustat-data",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 11, 2025 9:40am",
      "snippet": "FibroGen has agreed to pay $1.25 million to the Securities and Exchange Commission to address allegations that its former chief medical officer manipulated data for the anemia drug roxadustat.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "BKQVSNU6",
      "url": "https://www.fiercepharma.com/manufacturing/suns-gujarat-facility-put-fda-import-alert-ongoing-contamination-issues",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 11, 2025 9:00am",
      "snippet": "Ongoing issues at Sun Pharma’s production facility in Gujarat, India, have resulted in the FDA putting the facility on import alert status.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "CW7W5f8_",
      "url": "https://www.fiercepharma.com/marketing/sanofi-gilead-acadia-win-big-2025-fierce-pharma-marketing-awards",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 11, 2025 7:29am",
      "snippet": "This year’s Fierce Pharma Marketing Awards gala, which took place in Philadelphia on Wednesday night, saw several major drugmakers take home trophies.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "aojJgiNI",
      "url": "https://www.fiercepharma.com/manufacturing/api-maker-hikal-slammed-warning-letter-after-repeated-complaints-contamination",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 11, 2025 8:10am",
      "snippet": "India’s Hikal Limited has been hit with a warning letter from the FDA that chided the API drugmaker for failing to uncover the cause of almost two dozen complaints of metal contamination in its products.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6000000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 1,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "CwfS4Kfn",
      "url": "https://www.fiercepharma.com/biotech/merck-executes-its-own-brexit-moving-all-rd-operations-out-uk",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 10, 2025 3:21pm",
      "snippet": "Less than two years after breaking ground on a ballyhooed 1 billion pound sterling ($1.31 billion) R&amp;D center and future U.K. headquarters in London, Merck is not only bailing on the project but is discontinuing all of its research operations in Britain, citing an unwelcoming",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "4jGnS75L",
      "url": "https://www.fiercepharma.com/pharma/first-pd-1xvegfs-sake-summit-must-submit-big-pharma-stat",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 10, 2025 1:57pm",
      "snippet": "The highly debatable HARMONi data, along with the trial design flaws and the unfortunate execution they reflect, plus a rapidly evolving competitive landscape, all point to one conclusion: Summit must partner with a Big Pharma company as soon as possible.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "vuHEAOhr",
      "url": "https://www.fiercepharma.com/marketing/pharmas-looking-break-through-clutter-and-reach-patients-relatability-key",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 10, 2025 1:41pm",
      "snippet": "To really move the needle and reach consumers, it’s critical that ad spots come with a clear sense of authenticity and relatability in addition to the glitz and glam of Hollywood fame, experts said during a panel at Fierce Pharma Week.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "EuREO2D9",
      "url": "https://www.fiercepharma.com/marketing/landmines-everywhere-how-pharma-communications-keep-under-political-spotlight",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 10, 2025 12:11pm",
      "snippet": "Industry media leads joined a Fierce Pharma Week panel to discuss their shifting communication strategies amid an unfamiliar and turbulent political and policy era.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "ZUks3oUB",
      "url": "https://www.fiercepharma.com/marketing/trump-directs-fda-limit-dtc-drug-advertising-legal-challenges-sure-follow",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 10, 2025 11:05am",
      "snippet": "President Donald Trump has delivered another blow in his ongoing battle with the pharma industry, signing a memorandum on Tuesday that directs the FDA to rein in direct-to-consumer (DTC) drug advertising.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "jnCHOEaD",
      "url": "https://www.fiercepharma.com/pharma/johnson-johnsons-practice-changing-bladder-cancer-drug-device-combo-inlexzo-crosses-fda",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 10, 2025 9:49am",
      "snippet": "The drug-releasing system combo is approved to treat patients with bladder cancer who face removal of the organ after not responding to the standard-of-care Bacillus Calmette-Guérin treatment in the first-line setting.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "lRNC0WCW",
      "url": "https://www.fiercepharma.com/biotech/trump-admin-mulls-severe-restrictions-us-pharmas-securing-chinese-meds-nyt",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 10, 2025 8:43am",
      "snippet": "The Trump administration is considering putting “severe restrictions” on the increasing flow of investigational drugs from China, according to reporting by The New York Times.",
      "kind": "market",
      "category": "market",
      "priority": 0.45,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 1,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "W2TtPscu",
      "url": "https://www.fiercepharma.com/pharma/novo-nordisk-lay-9000-workers-new-ceo-aims-save-13b-year-late-2026",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 10, 2025 8:39am",
      "snippet": "In a bid to save around 8 billion Danish kroner ($1.3 billion) annually by the end of 2026, Novo will lay off roughly 9,000 employees across its global workforce of 78,400. Some 5,000 job cuts will occur in Novo’s home country of Denmark, the company said.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "eJ97Wf1s",
      "url": "https://www.fiercepharma.com/pharma/takeda-faces-another-pay-delay-antitrust-lawsuit-one-cvs-over-heartburn-drug-dexilant",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 10, 2025 7:07am",
      "snippet": "Six months after Walgreens and three other retailers&nbsp;brought an antitrust lawsuit against Takeda and TWi Pharmaceuticals over an alleged “pay-for-delay” scheme, CVS has filed a similar antitrust complaint against the same companies.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "QnqxHiZU",
      "url": "https://www.fiercepharma.com/marketing/rising-stars-how-arc-bios-kareem-clark-uses-his-neuroscience-background-help-clients",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 9, 2025 4:12pm",
      "snippet": "In a Q&amp;A for Fierce Pharma Marketing’s “Rising Stars” series, Kareem Clark explained how the pandemic led him to understand the importance of communicating scientific advances, and why he thinks agencies need to work harder to use the talents of all their employees.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "ZZ2RJRZn",
      "url": "https://www.fiercebiotech.com/biotech/arrowhead-battles-ionis-over-patent-dispute-tied-rnai-candidate-could-rival-tryngolza",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 11, 2025 11:01am",
      "snippet": "Arrowhead Pharmaceuticals has launched legal action against Ionis Pharmaceuticals, aiming to neutralize Ionis' claim that Arrowhead's potential rival to Tryngolza breaches a patent.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Ey44iJcy",
      "url": "https://www.fiercebiotech.com/biotech/fibrogen-pays-sec-12m-over-allegations-former-exec-reverse-engineered-roxadustat-data",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 11, 2025 9:40am",
      "snippet": "FibroGen has agreed to pay $1.25 million to the Securities and Exchange Commission to address allegations that its former chief medical officer manipulated data for the anemia drug roxadustat.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "8uaQUtI3",
      "url": "https://www.fiercebiotech.com/biotech/capsida-pauses-phase-1-gene-therapy-trial-after-child-dies",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 11, 2025 7:08am",
      "snippet": "Capsida Biotherapeutics has paused a gene therapy clinical trial after the first patient died. The biotech, which began the phase 1/2 study in July, took the action to give it time to determine the root cause of the death.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "43mqwSV2",
      "url": "https://www.fiercebiotech.com/biotech/lb-pharmaceuticals-upsizes-ipo-285m-first-biotech-listing-months",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 11, 2025 4:11am",
      "snippet": "LB Pharmaceuticals’ decision to break cover and go public seems to have paid off, with the company bumping up the number of shares on offer for its Nasdaq listing this morning.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "YCCkDSuz",
      "url": "https://www.fiercebiotech.com/biotech/uk-life-sci-investments-lag-abpi-spotlights-countrys-competitive-pitfalls",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 10, 2025 3:08pm",
      "snippet": "One week after warning that the United Kingdom is undervaluing life sciences manufacturing investments, trade organization the Association of the British Pharmaceutical Industry has issued another call to action for policymakers and the local biopharma scene.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "2ESo6UBt",
      "url": "https://www.fiercebiotech.com/biotech/merck-executes-its-own-brexit-moving-all-rd-operations-out-uk",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 10, 2025 3:21pm",
      "snippet": "Less than two years after breaking ground on a ballyhooed 1 billion pound sterling ($1.31 billion) R&amp;D center and future U.K. headquarters in London, Merck is not only bailing on the project but is discontinuing all of its research operations in Britain, citing an unwelcoming",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "LFe9pGRA",
      "url": "https://www.fiercebiotech.com/pharma/first-pd-1xvegfs-sake-summit-must-submit-big-pharma-stat",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 10, 2025 1:57pm",
      "snippet": "The highly debatable HARMONi data, along with the trial design flaws and the unfortunate execution they reflect, plus a rapidly evolving competitive landscape, all point to one conclusion: Summit must partner with a Big Pharma company as soon as possible.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "QzNef0p-",
      "url": "https://www.fiercebiotech.com/cro/iqvia-unveils-ai-suite-managing-clinical-trial-finances",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 10, 2025 2:29pm",
      "snippet": "IQVIA is unveiling a new suite of tools designed to manage all the financial components of clinical trials.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Qho9iULj",
      "url": "https://www.fiercebiotech.com/cro/phasev-launches-trial-optimizing-software-cro-bioforums-offerings",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 10, 2025 11:45am",
      "snippet": "Clinical software developer PhaseV is teaming up with another global CRO, unveiling a plan to infuse its trial design platform into Bioforum’s services.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "b62EnRZh",
      "url": "https://www.fiercebiotech.com/biotech/mei-pharma-leaves-biotech-woes-behind-rebrand-crypto-company",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 10, 2025 10:01am",
      "snippet": "From now on, MEI Pharma—previously best known for its clinical-stage leukemia drug—will be called Lite Strategy.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "mes66xVy",
      "url": "https://www.fiercebiotech.com/biotech/pmv-plots-ovarian-cancer-filing-after-seeing-midphase-data",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 10, 2025 9:22am",
      "snippet": "PMV Pharmaceuticals has reported a 43% response rate in a midphase ovarian cancer trial, putting the biotech on a track it believes will lead to a filing for FDA approval in the first quarter of 2027.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "QRvcMPL-",
      "url": "https://www.fiercebiotech.com/biotech/trump-admin-mulls-severe-restrictions-us-pharmas-securing-chinese-meds-nyt",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 10, 2025 8:43am",
      "snippet": "The Trump administration is considering putting “severe restrictions” on the increasing flow of investigational drugs from China, according to reporting by The New York Times.",
      "kind": "market",
      "category": "market",
      "priority": 0.45,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 1,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Hjzte--p",
      "url": "https://www.fiercebiotech.com/pharma/novo-nordisk-lay-9000-workers-new-ceo-aims-save-13b-year-late-2026",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 10, 2025 8:39am",
      "snippet": "In a bid to save around 8 billion Danish kroner ($1.3 billion) annually by the end of 2026, Novo will lay off roughly 9,000 employees across its global workforce of 78,400. Some 5,000 job cuts will occur in Novo’s home country of Denmark, the company said.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "QK_HsBNo",
      "url": "https://www.fiercebiotech.com/biotech/odyssey-therapeutics-heralds-213m-series-d-strengthen-clinical-portfolio",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 9, 2025 5:51pm",
      "snippet": "Odyssey Therapeutics’ team of seasoned drug developers is welcoming another impressive fundraising round, closing a $213 million series D round after abandoning plans to go public this summer.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "M-Nf3lsz",
      "url": "https://www.fiercebiotech.com/biotech/capricor-shares-response-cell-therapy-denial-after-fda-publicly-releases-rejection-letter",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 9, 2025 11:13am",
      "snippet": "Capricor Therapeutics has publicly released its July response to the FDA's rejection of its Duchenne muscular dystrophy cell therapy deramiocel after the agency included deramiocel in a new batch of complete response letters released Sept. 4.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "44DoGSaH",
      "url": "https://www.fiercepharma.com/marketing/keep-doing-what-youre-doing-marketing-policy-experts-talk-defense-against-threats-dtc",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 12, 2025 3:18pm",
      "snippet": "In a Fierce Pharma Week panel, experts including Coalition for Healthcare Communication Director James Potter discussed why President Donald Trump's threats to drug advertising may be more bark than bite.",
      "kind": "market",
      "category": "market",
      "priority": 0.45,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 1,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "MRGaZq_X",
      "url": "https://www.fiercepharma.com/pharma/trump-officials-eye-connection-between-covid-shots-infant-deaths-ahead-acip-meeting-wapo",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 12, 2025 2:15pm",
      "snippet": "As Robert F. Kennedy Jr.’s revamped CDC vaccine advisory panel gears up to meet next week, U.S. health officials are reportedly planning to connect the deaths of 25 children to the use of COVID shots.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "nY5BmDRL",
      "url": "https://www.fiercepharma.com/marketing/chronic-disease-treatment-ads-have-sparked-action-two-thirds-patients-survey",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 12, 2025 12:20pm",
      "snippet": "Amid the Trump administration’s call for a crackdown on direct-to-consumer pharmaceutical advertising, a new survey shows that many people with chronic conditions have been inspired by such ads to take some sort of action for their health.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Sa5gAbdA",
      "url": "https://www.fiercepharma.com/marketing/doctor-mike-calls-healthcare-pharma-leaders-lean-social-media-rebuild-trust",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 11, 2025 4:54pm",
      "snippet": "In the current climate, there is an urgent need for credible voices online, Doctor Mike noted in a discussion at Fierce Pharma Week. But the key is to create content that is transparent, authentic, educational and valuable.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Aycj6XCj",
      "url": "https://www.fiercepharma.com/pharma/gilead-prevails-whistleblower-lawsuit-over-alleged-hepatitis-c-prescription-kickbacks",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 12, 2025 11:06am",
      "snippet": "A federal judge granted Gilead summary judgment in a lawsuit that claimed the company used sham speaker events to induce doctors to write hepatitis C drug prescriptions.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "pjKY5niR",
      "url": "https://www.fiercepharma.com/pharma/trump-mulls-crackdown-china-deals-daiichi-mercks-adc-win-suns-import-ban",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 11, 2025 3:10pm",
      "snippet": "The Trump administration is reportedly weighing an executive order to limit drug licensing deals with China biotechs. Daiichi Sankyo and Merck are angling for an FDA accelerated approval for their B7-H3 ADC. Sun Pharma's beleaguered Halol plant has been slapped with an FDA import",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "vVwOyY0U",
      "url": "https://www.fiercebiotech.com/biotech/astrazeneca-pauses-271m-expansion-uk-latest-big-pharma-buck-britain",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 12, 2025 2:20pm",
      "snippet": "AstraZeneca has paused a 200 million pound sterling (about $271 million) investment in its Cambridge, England, research site, the latest Big Pharma to pull back from the U.K. this week, a company spokesperson has confirmed to Fierce Biotech.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "wAijvgNa",
      "url": "https://www.fiercebiotech.com/medtech/neurescues-resuscitation-device-nets-eu-approval-non-shockable-cardiac-arrests",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 12, 2025 1:08pm",
      "snippet": "Neurescue has been working for over a decade to develop an easy-to-use system capable of directing oxygenated blood to the heart and brain when it’s needed most.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6000000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 1,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "EB7EqfpW",
      "url": "https://www.fiercebiotech.com/biotech/eli-lilly-reconsiders-uk-biotech-incubator-pauses-buildout-report",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 12, 2025 11:42am",
      "snippet": "Eli Lilly is reconsidering plans for its U.K. biotech-focused Gateway Labs amid concerns about the industry’s outlook in the country and low government spend on drug development, according to reports from several outlets.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "_sM8w7qG",
      "url": "https://www.fiercebiotech.com/biotech/galimedix-seeks-phase-2-funding-after-oral-alzheimers-candidate-clears-safety-test",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 12, 2025 11:00am",
      "snippet": "Maryland-based biotech Galimedix Therapeutics is ready to take a big swing on its oral Alzheimer’s disease candidate after the small molecule caused no serious adverse events and successfully crossed the blood-brain barrier in a phase 1 trial.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "3XTOjnTu",
      "url": "https://www.fiercebiotech.com/biotech/chutes-ladders-takeda-taps-longtime-lilly-exec-us-head",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 11, 2025 4:55pm",
      "snippet": "With its head of U.S. business Julie Kim sliding up to the CEO spot next June, Takeda has locked in a replacement in Rhona Pacheco. Pacheco is set to leave behind her role as Eli Lilly’s VP of U.S. cardiometabolic health, the most recent title she’s held along her 20-year tenure ",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    }
  ],
  "last_run_at": "2025-09-13T15:47:15.879Z"
}